diabetes
Overview
Diabetes mellitus is a chronic metabolic disease of impaired glucose regulation, defined by persistent hyperglycemia arising from defects in insulin secretion, insulin action, or both. Diagnosis rests on threshold values of fasting or post-load glucose or of glycated hemoglobin (HbA1c), the same measure used to judge control thereafter. In type 1 diabetes, autoimmune destruction of pancreatic β-cells produces absolute insulin deficiency and an absolute requirement for replacement; type 2 diabetes, which accounts for the large majority of cases, combines insulin resistance with progressive β-cell failure, so hyperglycemia appears only once secretion can no longer compensate. Other forms include gestational diabetes, monogenic diabetes of the young, and diabetes secondary to pancreatic disease or drugs. Hypoglycemia is largely a hazard of treatment rather than of the disease, which is why regimens that raise insulin levels independently of glucose demand more monitoring than those that do not.
The disease matters clinically because of what sustained hyperglycemia does to vessels and nerves. Microvascular complications — diabetic nephropathy, diabetic retinopathy and neuropathy — arise from small-vessel and neural injury, while macrovascular disease brings coronary artery disease, myocardial infarction, stroke and peripheral artery disease. Diabetic foot ulceration sits at the junction of the two, following from neuropathy that removes protective sensation together with impaired perfusion, and is the leading cause of non-traumatic amputation. Diabetes also affects pregnancy outcomes, bone healing, liver and kidney function, and quality of life.
Management combines glycemic control with organ protection, and the two aims no longer coincide automatically. The biguanide metformin remains the usual first agent in type 2 disease, but sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists are now chosen for demonstrated cardiovascular and renal benefit that exceeds what their glucose lowering alone would predict, which has shifted treatment selection from a purely glucose-centered logic toward the complications being prevented.
Recent Publications Summary
Recent publications have examined diabetes in a range of clinical, epidemiologic, and risk-stratification contexts. In a large Korean national cohort, self-reported diabetes history was compared with medical claims records and found to be substantially underreported relative to claims-based prevalence, with low sensitivity but relatively high specificity, highlighting misclassification concerns in survey-based research 42576717Aug. In older adults from five harmonized cohorts, diabetes was evaluated alongside other vascular risk factors for associations with white matter tract microstructure; diabetes-related associations were observed initially but were attenuated in sensitivity analyses, whereas hypertension and heart disease showed the most robust and widespread effects 42535262Jul.
Several studies focused on diabetes as a predictor of complications or comorbidity risk. In a propensity score-matched cohort of more than six million adults, diabetes was associated with increased risk of carpal tunnel syndrome, ulnar nerve entrapment, tarsal tunnel syndrome, and radial nerve entrapment, with the strongest associations seen for carpal tunnel syndrome and tarsal tunnel syndrome in adults younger than 40 years 42385534Jul. In colorectal cancer surgery, postoperative hyperglycemia was associated with higher complication rates, and diabetes duration was examined as a predictor of postoperative outcomes alongside nutritional recovery, indicating interest in how diabetes-related metabolic status affects surgical recovery 42484705Jul. In head and neck cancer patients receiving radiotherapy, diabetes was associated with the onset severity of oral mucositis and also with peak severity, suggesting a role for diabetes in treatment-related toxicity 42056592Apr.
Other publications addressed diabetes risk prediction and self-management-related decision support. A Brazilian cohort study developed a multistage diabetes risk staging schema using the Finnish Diabetes Risk Score with fasting and 1-hour oral glucose tolerance test glucose values; the approach identified graded increases in incident diabetes risk and reduced the need for OGTT testing when screening began with FINDRISC 42309180Jun. A decision aid was also developed to help dually enrolled veterans with diabetes choose how to source medications through the VA, Medicare Part D, or both, reflecting efforts to support informed medication access decisions 42043925Apr. In addition, a cross-sectional study examined supportive care needs among family caregivers of elderly patients with dementia and diabetes mellitus 42048613Apr, while a separate study characterized continuous glucose monitoring metrics in adolescents with obesity without diabetes 41928639Apr, and a cost-effectiveness analysis evaluated continuous glucose monitoring with remote patient monitoring in newly diagnosed pediatric type 1 diabetes in the U.S. 41879358Mar.
What Changes, What Holds
1. Claims data appear more reliable than self-report for diabetes surveillance, and diabetes’ white-matter signal is not yet secure
METHOD Self-reported diabetes history substantially undercounted prevalence against claims records, so epidemiologic work using surveys alone risks misclassification and may need linkage or validation. The neuroimaging finding is more tentative: diabetes-related white-matter microstructure differences weakened after sensitivity analyses, leaving hypertension and heart disease as the more reproducible vascular correlates in these cohorts 42576717Aug42535262Jul.
2. Diabetes adds measurable risk for several nerve entrapment syndromes and worsens some treatment-related recovery outcomes
NEW DIRECTION Diabetes is now implicated in peripheral entrapment neuropathies beyond the classic microvascular and generalized neuropathy framework, especially carpal tunnel and tarsal tunnel syndromes, with stronger signals in younger adults 42385534Jul. The surgical and radiotherapy findings extend the complication profile further: postoperative hyperglycemia and diabetes duration may matter for recovery after colorectal surgery, and diabetes appears to increase both onset and peak severity of oral mucositis during head and neck radiotherapy 42484705Jul42056592Apr.
3. Multistage screening can reduce OGTT use, and diabetes is moving into access and supportive-care decision tools
NEW DIRECTION A staged risk algorithm built around FINDRISC plus selective glucose testing suggests that diabetes case-finding can be made less intensive without losing graded risk stratification, which could change how screening is organized 42309180Jun. The remaining studies do not alter disease biology, but they show diabetes increasingly shaping medication-access decisions and caregiving support, while related CGM work in obesity and pediatric type 1 diabetes reflects expanding monitoring and cost-effectiveness questions rather than new core disease concepts 42043925Apr42048613Apr41928639Apr41879358Mar.
Overview update candidates: diabetes as a risk factor for entrapment neuropathies; diabetes worsening radiotherapy mucositis; staged screening to reduce OGTT use; misclassification concerns in survey-based diabetes prevalence estimates.
diabetes
Background Contexts
In the literature, the biological baseline, pathological conditions, or disease models commonly surrounding diabetes are described as follows:
- type 2 diabetes (Disease) — 6 papers: PMIDs 42544575, 42336271, 42309180, 42283639, etc.
- cardiovascular disease (Disease) — 5 papers: PMIDs 42563426, 42522413, 42507733, 42498467, etc.
- diabetic foot ulcer (Disease) — 5 papers: PMIDs 42521882, 42492077, 42482123, 42049636, etc.
- insulin (Protein) — 5 papers: PMIDs 42547502, 42543084, 42251764, 42229656, etc.
- obesity (Disease) — 5 papers: PMIDs 42580835, 42570075, 42567881, 42557543, etc.
- stroke (Disease) — 5 papers: PMIDs 42507733, 42507057, 42489810, 42251764, etc.
- hyperglycemia (Biological Process) — 4 papers: PMIDs 42521616, 42483964, 42153489, 41732673
- type-1 diabetes (Disease) — 4 papers: PMIDs 42555595, 42544575, 42485542, 42108331
- arterial hypertension (Disease) — 3 papers: PMIDs 42055612, 41947488, 41879409
- atherosclerosis (Disease) — 3 papers: PMIDs 42507733, 42507057, 42251764
- chronic kidney disease (Disease) — 3 papers: PMIDs 42580835, 42571988, 42108331
- diabetic nephropathy (Disease) — 3 papers: PMIDs 42361854, 42172900, 41912450
Methodologies & Technologies Used
Researchers utilize the following experimental methods, imaging platforms, computational models, or biological reagents to study diabetes:
- Age (Other) — 8 papers: PMIDs 42571988, 42543084, 42507057, 42485372, etc.
- continuous glucose monitor (Technology) — 8 papers: PMIDs 42555595, 42336271, 42153489, 42108331, etc.
- α-streptozocin (Chemical) — 8 papers: PMIDs 42547502, 42485542, 42389811, 42341385, etc.
- artificial intelligence (Technology) — 4 papers: PMIDs 42532593, 42516116, 42475533, 40685494
- body mass index (Clinical Metric) — 4 papers: PMIDs 42580835, 42543084, 42485372, 42201287
- hemoglobin A1c (Clinical Metric) — 3 papers: PMIDs 42567881, 42274313, 42257579
- high-fat diet (Other) — 3 papers: PMIDs 42483964, 42389811, 42336033
- human (Organism) — 3 papers: PMIDs 42563426, 42547502, 42544575
- hypertension (Disease) — 3 papers: PMIDs 42535419, 42507057, 42482123
- machine learning (Technology) — 3 papers: PMIDs 42507733, 42489810, 42257579
- mice (Organism) — 3 papers: PMIDs 42544575, 42485542, 42336033
- mouse (Organism) — 3 papers: PMIDs 42563426, 42547502, 42283639
Molecular Interventions & Targets
The primary molecular pathways, regulatory genes, enzymes, or therapeutic agents actively targeted and manipulated in relation to diabetes include:
- sodium glucose cotransporter-2 (SGLT2) inhibitors (Therapy) — 3 papers: PMIDs 42049990, 41879409, 41816887
- All-cause mortality (Clinical Metric) — 2 papers: PMIDs 42455491, 41842751
- dapagliflozin (Chemical) — 2 papers: PMIDs 42341385, 42172900
- diabetic foot ulcer (Disease) — 2 papers: PMIDs 42521882, 42482123
- glucagon-like peptide 1 receptor agonist (Therapy) — 2 papers: PMIDs 42498467, 42395062
- hypertension (Disease) — 2 papers: PMIDs 42576717, 42535262
- ischemic stroke (Disease) — 2 papers: PMIDs 42522413, 42455491
- quercetin (Chemical) — 2 papers: PMIDs 42021540, 41732673
- 1 h Plasma Glucose (Clinical Metric) — 1 paper: PMIDs 42309180
- Acid α-glucosidase (AAG) (Protein) — 1 paper: PMIDs 42047278
- acute kidney injury (Disease) — 1 paper: PMIDs 42049410
- ADAMTS13 (Protein) — 1 paper: PMIDs 41912450
Observed Outcomes & Phenotypes
The phenotypic changes, physiological endpoints, or clinical metrics observed and measured in connection with diabetes include:
- Age (Other) — 5 papers: PMIDs 42535419, 42498935, 42495104, 42492077, etc.
- hazard ratio (Clinical Metric) — 5 papers: PMIDs 42495104, 42485372, 42455491, 42385534, etc.
- hemoglobin A1c (Clinical Metric) — 5 papers: PMIDs 42535419, 42336271, 42309180, 41985893, etc.
- body mass index (Clinical Metric) — 4 papers: PMIDs 42567881, 42535419, 42535262, 42486793
- glycemic control (Clinical Metric) — 4 papers: PMIDs 42285381, 42054697, 42049636, 42047278
- insulin (Protein) — 4 papers: PMIDs 42550869, 42301155, 42153489, 41626659
- albuminuria (Clinical Metric) — 3 papers: PMIDs 42571988, 42535419, 41921465
- heart failure (Disease) — 3 papers: PMIDs 42498935, 42455491, 42201287
- hyperglycemia (Biological Process) — 3 papers: PMIDs 42547502, 42484705, 42153489
- hypertension (Disease) — 3 papers: PMIDs 42535262, 42522227, 42455491
- hypoglycemia (Disease) — 3 papers: PMIDs 42108331, 42054697, 41957663
- insulin resistance (Biological Process) — 3 papers: PMIDs 42336106, 42336033, 42153489
General Takeaways & Clinical Potentials
The high-level concepts, clinical translations, and overarching conclusions proposed in the research surrounding diabetes are summarized below:
- Mortality (Clinical Metric) — 3 papers: PMIDs 42571988, 42498935, 42482123
- Clinical Practice (Other) — 2 papers: PMIDs 42576717, 41957663
- diabetic cardiomyopathy (Disease) — 2 papers: PMIDs 42389811, 42336033
- diabetic foot ulcer (Disease) — 2 papers: PMIDs 42521882, 42482123
- external validation (Other) — 2 papers: PMIDs 42535419, 42257579
- glucagon-like peptide-1 agonist (Therapy) — 2 papers: PMIDs 42570075, 42557543
- inflammation (Biological Process) — 2 papers: PMIDs 42485542, 42483964
- mitophagy (Biological Process) — 2 papers: PMIDs 41912450, 41906653
- obesity (Disease) — 2 papers: PMIDs 42567881, 42557543
- type 2 diabetes (Disease) — 2 papers: PMIDs 42483964, 42336271
- 1 h Plasma Glucose (Clinical Metric) — 1 paper: PMIDs 42309180
- 9 cardiovascular and mortality outcomes (Other) — 1 paper: PMIDs 42201287